A good read CBCI

No matter what, when, where, our Nurse Practitioners are there, leading the way and taking care of our patients. This #NPWeek we couldn't be more thankful for our fantastic NPs!

Colorado Woman Tackles 14ers While Going Through Leukemia Treatment kool1079.com/colorado-woman… @kool1079

Nonclassical manifestations of acute #GVHD loom.ly/skDwqcs

We have specially-trained nurses ready to help you with any cancer questions and who can get you connected with the right resources. Call us at (844)482-4814. #askSARAH #CancerResources

Excellent presentation regarding the MDS prognostication. I always felt the gap of an MDS prognostic system with molecular data incorporated. #ASH21 #MDSsm CBCI Sarah Cannon Docs

As for the first day of presentations it felt so good to be back to in person #ASH21 and meet old co fellows and colleagues however nothing super excitingly was new in the MDS/leukemia world that I could find! I found these presentations interesting #MDSsm Sarah Cannon Docs

#ASH21 Exhibit Hall open today 10-2. Stop by Sarah Cannon Docs Booth 1117 to learn more about our expansive blood 🩸 cancer network & opportunities available to join/partner with us across the country!@BldCancerDoc @LemaistreFred Rocky Billups #FightingBloodCancerTogether

CONGRESS | #ASH2021 | Raúl Azibeiro Melchor, shows co-mutation of RAD21 in DNMT3A mutated #AML has a positive effect on survival, independent of NPM1 co-occurrence. #leusm

So refreshing the mind to walk out the convention center to a sunny semi cold sunny weather with a great live music after listening to great talks but with an exhausted brain!! 😎#ASH21 CBCI Sarah Cannon Docs

Dr. Tareq Abuasab presents the phase I/II Study of CLIA + Gilteritinib in newly diagnosed fit AML, demonstrating high MRD (-) CR rates when combining gilt with intensive chemo in frontline.

Outstanding data by Dr. Alexandre Bazinet reporting on the 1st study of low dose AZA-Ven as MAINTENANCE therapy in AML for pts in remission after initial induction/consolidation

Great presentations by Dr. Borate and Dr. Bejar on clonal hematopiesis and response assessment in MDS at Acute Leukemia Forum #ALFlive22 #MDSsm CBCI Sarah Cannon Docs

The last day of a great educational lymphoma program #PPLC22 #IamUNMC The highlight: a debate between Drs. Abramson and Sauter about AutoHCT vs CAR T Tx where Dr. Abramson’s phone rang and he said” hey Craig, 80s calling and wants his transplant back!!”😂 Sarah Cannon Docs

An important ongoing issue ASTCT CBCI

A 2nd allo-HCT is a reasonable option for relapsed AML. It is more effective if done in CR. Efficacy of a second allogeneic hematopoietic cell transplant in relap... sciencedirect.com/science/articl… Bipin Savani Mohamad Mohty Wael Saber Farah Yassine Ernesto Ayala Mahmoud Aljurf Taiga Nishihori, MD

#MahsaAmini youtu.be/dsxJ0sF83HM

The iCMLf Conversation: CML Highlights of ASH is now available online in two parts. View the Clinical Overview led by Professor Michael Mauro here: bit.ly/3FUEdE1 and Biological Overview led by Professor Ravi Bhatia here: bit.ly/3YQi3eK

#Hematology Long‐term follow‐up demonstrates curative potential of autologous stem cell transplantation #ASCT for relapsed #follicular #lymphoma #lymsm #bmtsm onlinelibrary.wiley.com/doi/10.1111/bj…

A new model to predict survival after low-intensity chemoRx in older #AML published by Dr. Koji Sasaki of MD Anderson Cancer Center #Leukemia, ACS Journal Cancer online acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #leusm